Scientists have developed a new and improved chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma, a type of blood cancer. 1 This new therapy uses a third-generation CAR that targets a protein called BCMA found on myeloma cells. 1 The researchers found that their third-generation anti-BCMA CAR T-cells were more effective at killing myeloma cells than the current second-generation CAR T-cell therapies. 1 The third-generation CAR T-cells also showed improved persistence, meaning they remained active in the body for longer. 1 This could lead to better outcomes for patients with multiple myeloma. 1
Funding
This work was supported by Mahidol University’s Basic Research Fund (Fiscal Year 2022) [BRF1-029/2565], the Siriraj Research Fund of the Faculty of Medicine Siriraj Hospital, Mahidol University [R016034008], and the National Research Council of Thailand (NRCT) [N35E660102].
Original Paper
Title of original paper: Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma
Journal: Clinical and Experimental Medicine
DOI: https://doi.org/10.1007/s10238-024-01347-7